Live Breaking News & Updates on Eris lifesciences

Stay informed with the latest breaking news from Eris lifesciences on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Eris lifesciences and stay connected to the pulse of your community

ChrysCapital eyes stake in Delhi's Centre For Sight eye hospital

ChrysCapital's proposed investment will give an exit to Mahindra Partners, the PE arm of Mahindra & Mahindra, which owns about 32% stake in the chain. At present, Centre For Sight founder Dr Mahipal S Sachdev is the majority stakeholder with about 55% stake in the chain. Another 10% stake has been given under employee stock ownership plan.

India , Delhi , Madhya-pradesh , New-delhi , Uttar-pradesh , Mumbai , Maharashtra , Mahipals-sachdev , Intas-pharmaceuticals , Aragen-life-sciences , Mahindra , Lancet-global-health-commission

From Mumbai to Jaipur: Cities that have produced maximum self-made entrepreneurs

In the vibrant tapestry of India's entrepreneurial landscape, certain cities stand out as incubators for a remarkable phenomenon – the rise of self-made entrepreneurs.

Hyderabad , Andhra-pradesh , India , New-delhi , Delhi , Mumbai , Maharashtra , Bengaluru , Karnataka , Ahmedabad , Gujarat , Pune

nifty target: Nifty may cross 22,500 in 12 months, says Prabhudas Lilladher; picks Hindalco, 3 more stocks as conviction buys

Nifty is trading at a 17.2% discount to the 10-year average which provides comfort to Prabhudas who believes that the headline index is not trading in a bubble zone. The 50-stock index has remained flattish in the past 6 weeks and given just 1.6% return in the quarter gone by, riding on inflows of the domestic institutional investors (DIIs) even as the foreign institutional investors (FIIs) preferred selling the domestic equities, the note said.

India , Malaysia , Prabhudas-lilladher , Lok-sabha , El-nino , Maruti-suzuki , Westlife-foodworld , Axis-bank , Reliance-industries , Chalet-hotels , Sunteck-realty , Aarti-industries

Prabhudas Lilladher sees Nifty at 22,584 in 12 months; lists top stock picks

Indian market has taken all headwinds in its stride and the action has been very stock-specific as Mid/small caps continue to outperform large caps, Prabhudas Lilladher stated. It lists its top large, mid and smallcap picks for model portfolio.

India , Bharat , El-nino , Guj-fluro , Lok-sabha , Prabhudas-lilladher , Maruti-suzuki , Suntek-realty , Titan-company , Sunteck-realty , Siemens , Ashok-leyland

NPPA makes 33 fixed-dose combination drugs cheaper, brings them under regulation

The 33 drugs includes two each from JB Chemicals and Pharmaceuticals, Eris Lifesciences, Zydus Healthcare, Cipla, Sun Pharmaceutical, and Sanofi India and one from Torrent Pharma.

India , Delhi , Cipla , Delhi-high-court , Services-tax , National-pharmaceutical-pricing-authority , Eris-lifesciences , Zydus-healthcare , Sun-pharmaceutical , Sanofi-india , Maximum-retail-price

Biocon gains on UK health agency's marketing nod to subsidiary for ophthalmic biosimilar

Earlier in this month, Eris Lifesciences has signed a definitive agreement with Biocon Biologics to acquire its Branded Formulations’ India (BFI) business units of nephrology and dermatology.

Malaysia , India , United-kingdom , Biocon-biologics , European-union , Biocon , Regulatory-agency , European-commission , Eris-lifesciences , Branded-formulation-india , Biocon-share-price-today ,

Biocon Q2 results: Net profit more than doubles to Rs 172.7 crore

Biocon Q2 earnings: The company reported a profit of Rs 414.5crore in the same period of the previous year

Malaysia , Malaysian , Drug-administration , Biocon , Eris-lifesciences , Official-action-indicated , Biocon-q2-earnings , Iocon-q2-results , Iocon-q2-earnings-updates , Iocon-q2-results-updates , Iocon-quarterly-results

Biocon Biologics announces divestment

Biocon Biologics Limited , a subsidiary of Biocon Limited (BSE code: 532523, NSE: BIOCON), today announced that it has entered into a definitive agreement with Eris Lifesciences (Eris) for the divesture of its Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands. The transaction is a

India , Shreehas-tambe , Biocon-biologics , Amit-bakshi , Eris-lifesciences-ltd , Biocon , Biocon-limited , Biocon-biologics-limited , Eris-lifesciences , Slump-sale- , Branded-formulations , Managing-director

Biocon reports net profit of ₹172.7 crore in Q2 - The Hindu BusinessLine

Biocon reports net profit of ₹172.7 crore in Q2 - The Hindu BusinessLine
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

India , Biocon-biologics , Facebook , Twitter , Linkedin , Biocon , Eris-lifesciences ,

Stocks in news: Patanjali Foods, Adani Ports, Apollo Hospitals, ZEE, Biocon

Tata Power's consolidated net profit rose 7% year-on-year to Rs 876 crore in the three months ended September period.

India , Mazagon , Maharashtra , Biocon-biologics , Biocon , Pidilite-industries , Dalal-street , Apollo-hospital , Adani-ports , Eris-lifesciences , Tata-power , Patanjali-foods